Acute Myeloid Leukemia — Expanded Access Programs

• Study on 211^At-BC8-B10 Before Donor Stem Cell Transplant for High-Risk Leukemia and Related Conditions — Fred Hutchinson Cancer Center
• Phase II Study on Dual Inhibition of BCL2 and Menin in AML Using Venetoclax and Revumenib — M.D. Anderson Cancer Center
• Study on Oral Combination Treatment for Acute Myeloid Leukemia (AML) — M.D. Anderson Cancer Center
• Pilot Study on Using Decitabine and Filgrastim After Stem Cell Transplant in Children and Young Adults with Blood Cancers — Franziska Wachter
• Study for Participants Continuing ASTX727 Treatment from Previous Clinical Trials — Taiho Oncology, Inc.
• Study of ASTX030 (Cedazuridine and Azacitidine) for MDS, CMML, or AML — Taiho Oncology, Inc.
• A Study of BGB-11417 in Participants With Myeloid Malignancies — BeiGene
• A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML — Treadwell Therapeutics, Inc
• Study on CTX-712 for Treating Relapsed or Hard-to-Treat Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes — Chordia Therapeutics, Inc.
• Study on Revumenib and Mezigdomide for Treating Leukemia — Memorial Sloan Kettering Cancer Center
• Study on Revumenib for Treating Relapsed or Refractory Leukemias with Specific Gene Changes — Syndax Pharmaceuticals
• Study on Tagraxofusp with Venetoclax and Azacitidine for Adults with Untreated CD123+ Acute Myeloid Leukemia Who Cannot Have Intensive Chemotherapy — Stemline Therapeutics, Inc.
• Study on the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone for Treating Acute Myeloid Leukemia — Memorial Sloan Kettering Cancer Center
• Study on Venetoclax with Chemotherapy for Children with Acute Myeloid Leukemia — St. Jude Children's Research Hospital
• Study on the Safety and Effects of Pivekimab Sunirine with Venetoclax and Azacitidine for Treating Acute Myeloid Leukemia (AML) — AbbVie
• Study on the Safety and Effectiveness of Bexmarilimab Combined with Standard Treatment for Blood Cancers — Faron Pharmaceuticals Ltd
• Study on the Safety and Effectiveness of Debio 1562M for Treating Acute Myeloid Leukemia (AML) — Debiopharm International SA
• Study Comparing Standard Chemotherapy to CPX-351 and/or Gilteritinib for Newly Diagnosed Acute Myeloid Leukemia (AML) with or without FLT3 Mutations — Children's Oncology Group
• Study Comparing Oral Azacitidine Plus Supportive Care to Supportive Care Alone for Maintenance Therapy in Japanese Patients with Acute Myeloid Leukemia in Complete Remission — Bristol-Myers Squibb
• Study on Depleting Alpha/Beta T Cells and CD19+ B Cells in Stem Cell Transplants for Patients with Blood Cancers — University of Florida
• Extension Study for Patients Continuing Venetoclax Treatment from Previous Trials — AbbVie
• Study on ASTX727, Venetoclax, and Gilteritinib for Treating FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — M.D. Anderson Cancer Center
• Study on Azacitidine and Venetoclax as Ongoing Treatment for Patients with Acute Myeloid Leukemia in Remission — M.D. Anderson Cancer Center
• Study on Azacitidine and Enasidenib for Treating Patients with IDH2-Mutant Myelodysplastic Syndrome — M.D. Anderson Cancer Center
• Study on Azacitidine and Gemtuzumab Ozogamicin for Older Patients with Untreated Acute Myeloid Leukemia — National Cancer Institute (NCI)
• Study on Azacitidine or Decitabine with Venetoclax for Acute Myeloid Leukemia After Previous Treatment Failure — Brian Jonas
• Study on Adding Pembrolizumab to Standard Chemotherapy for Treating Acute Myeloid Leukemia — National Cancer Institute (NCI)
• Study on Bleximenib with Standard Chemotherapy for Treating Acute Myeloid Leukemia (AML) — Stichting Hemato-Oncologie voor Volwassenen Nederland
• Study on Chemotherapy and Total-Body Radiation Followed by Donor Stem Cell Transplant for Treating High-Risk Myeloid Cancers — Fred Hutchinson Cancer Center
• Study on Cladribine and Venetoclax for Treating Monocytic Acute Myeloid Leukemia (AML) — University of Colorado, Denver
• Study on Cladribine, Idarubicin, Cytarabine, and Quizartinib for Treating Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — M.D. Anderson Cancer Center
• Study on Cladribine, Idarubicin, Cytarabine, and Venetoclax for Treating Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia — M.D. Anderson Cancer Center
• Study on Chemotherapy and Radiation Therapy Followed by Donor Cell Transplant for Treating Older Adults with High-Risk Acute Myeloid Leukemia or Other Severe Blood Cancers — Fred Hutchinson Cancer Center
• Comparing Different Drug Combinations for Treating Younger Patients with Intermediate Risk Acute Myeloid Leukemia (AML) — National Cancer Institute (NCI)
• Study Comparing Different Treatment Durations of Venetoclax for Older Adults with Newly Diagnosed Acute Myeloid Leukemia — National Cancer Institute (NCI)
• Comparing New Treatments for Newly Diagnosed Acute Myeloid Leukemia with an IDH2 Gene Mutation — National Cancer Institute (NCI)
• Study on Adding Pomalidomide to Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia with Myelodysplastic Syndrome-Related Changes — National Cancer Institute (NCI)
• Study on Cord Blood Transplant with Chemotherapy and Radiation for Treating High-Risk Blood Diseases — Fred Hutchinson Cancer Center
• Study on Memory-like NK Cell Therapy After Partial Match Donor Stem Cell Transplant — Washington University School of Medicine
• Study on Cytokine-Induced Memory-Like Natural Killer Cells for Treating Relapsed or Hard-to-Treat Acute Myeloid Leukemia — Children's Hospital Medical Center, Cincinnati
• Study on Cytokine-Treated Veto Cells for Patients with Blood Cancers After Stem Cell Transplant — M.D. Anderson Cancer Center
• Study on Daunorubicin and Cytarabine With or Without Uproleselan for Treating Older Adults with Acute Myeloid Leukemia — National Cancer Institute (NCI)
• Study on Decitabine and Venetoclax as Maintenance Therapy After Stem Cell Transplant for Blood Cancer Patients — Benjamin Tomlinson
• Study on Decitabine with Ruxolitinib, Fedratinib, or Pacritinib for Treating Advanced Myeloproliferative Neoplasms — University of Washington
• Study on Decitabine, Cytarabine, and Daunorubicin for Treating Acute Myeloid Leukemia — National Cancer Institute (NCI)
• Study on Decitabine/Cedazuridine and Venetoclax with Ivosidenib or Enasidenib for Treating Relapsed or Resistant Acute Myeloid Leukemia — M.D. Anderson Cancer Center
• Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers — M.D. Anderson Cancer Center
• Study on Stopping Chemotherapy in Patients with Acute Myeloid Leukemia (AML) in Remission — H. Lee Moffitt Cancer Center and Research Institute
• Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for Treating Blood Cancers — Fred Hutchinson Cancer Center
• Study on Donor-Derived Natural Killer Cell Infusions for Children and Young Adults with High-Risk Acute Myeloid Leukemia Undergoing Transplant — Michael Pulsipher
• Study on Two Different Doses of Quizartinib for Maintenance in Acute Myeloid Leukemia Patients in Complete Remission — Daiichi Sankyo
• Expanded Access Program for Galinpepimut-S in Patients with AML or MDS — Sellas Life Sciences Group
• First Human Study of Ziftomenib for Treating Relapsed or Hard-to-Treat Acute Myeloid Leukemia — Kura Oncology, Inc.
• Study on Using FLT PET/CT Scans to Measure Treatment Response in Patients with Untreated Acute Myeloid Leukemia — National Cancer Institute (NCI)
• Study on Fractionated Gemtuzumab Ozogamicin for Treating Residual Disease in Acute Myeloid Leukemia Patients — University of Washington
• Study Comparing Galinpepimut-S to Best Available Therapy for Maintenance in Acute Myeloid Leukemia (AML) in Second Remission — Sellas Life Sciences Group
• Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) — Fred Hutchinson Cancer Center
• Study on HLA-Mismatched Unrelated Donor Stem Cell Transplant with Reduced Cyclophosphamide for Graft Versus Host Disease Prevention — Center for International Blood and Marrow Transplant Research
• Study on Different Treatment Orders for Newly Diagnosed IDH Mutated AML Patients Not Suitable for Intensive Therapy — Alice Mims
• Study on Improving Risk Assessment in AML Using Precision Genomic Strategy to Check Mutation Clearance — Washington University School of Medicine
• Study on Using Fludarabine, Cytarabine, Idarubicin, and Venetoclax for Treating Acute Myeloid Leukemia — OHSU Knight Cancer Institute
• Using Interferon-γ and Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes After Stem Cell Transplant — Sawa Ito, MD
• Study on Ivosidenib and Venetoclax With or Without Azacitidine for Treating Blood Cancers with IDH1 Mutation — M.D. Anderson Cancer Center
• Ivosidenib Access Program for Patients with Relapsed or Hard-to-Treat AML with an IDH1 Mutation — Agios Pharmaceuticals, Inc.
• Study on Using KIR-Favorable Donors for Transplants in Children with Certain Blood Cancers — Michael Pulsipher
• Study on Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for Treating Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome — M.D. Anderson Cancer Center
• Study on Low Dose Weekly Decitabine and Venetoclax for Treating MDS and AML — Montefiore Medical Center
• Comparing Stem Cell Transplant Options for Young People with Acute Leukemia or Myelodysplastic Syndrome — Children's Oncology Group
• Study on T Cell Receptor Alpha/Beta Depletion Stem Cell Transplant for Blood Cancers — Masonic Cancer Center, University of Minnesota
• Study on Using Reduced Intensity Conditioning and Stem Cell Transplant for Treating Blood Diseases — Masonic Cancer Center, University of Minnesota
• Study on Myeloablative Stem Cell Transplant with Donor for Blood Disorders — Masonic Cancer Center, University of Minnesota
• MYELOMATCH: Screening Study for Myeloid Cancer Treatment Options — National Cancer Institute (NCI)
• Study on Olutasidenib and Azacitidine for Treating IDH1-Mutated Acute Myeloid Leukemia After Previous Treatment — University of California, Davis
• Study on Olutasidenib, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia with IDH1 Mutation — Justin Watts, MD
• Study on Oral Azacitidine for Transplant-Eligible Patients with Acute Myeloid Leukemia Facing Health Inequality — Virginia Commonwealth University
• Study on the Safety and Effectiveness of ASTX727 and Venetoclax for Treating Acute Myeloid Leukemia (AML) — Taiho Oncology, Inc.
• Study on Proteasome Inhibitor and CPX-351 for Treating Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia (AML) — Masonic Cancer Center, University of Minnesota
• Pilot Study of Memory-like Natural Killer Cells After Half-Matched Family Stem Cell Transplant in High-Risk Acute Myeloid Leukemia — Washington University School of Medicine
• Study on Orca-T for Patients Undergoing Stem Cell Transplant for Blood Cancers — Orca Biosystems, Inc.
• Study on Reduced-Intensity Conditioning to Lower Treatment-Related Deaths in Patients Undergoing Stem Cell Transplant — Thomas Jefferson University
• Ruxolitinib + Allogeneic Stem Cell Transplantation in AML — Massachusetts General Hospital
• Study on Ruxolitinib with Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease in Young Patients Undergoing Bone Marrow Transplant for Leukemia or Myelodysplastic Syndrome — City of Hope Medical Center
• Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML — Nationwide Children's Hospital
• Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML) — Daiichi Sankyo
• Study on Using Intensity Modulated Total Marrow Irradiation with Fludarabine/Busulfan for Transplant in High-Risk AML and Myelodysplastic Syndromes — University of Illinois at Chicago
• Study on CCS1477 for Blood Cancers — CellCentric Ltd.
• Study on Tagraxofusp and Azacitidine With or Without Venetoclax for Newly Diagnosed Secondary AML After Previous Treatment — Joshua Zeidner
• Study on Using Nivolumab to Prevent Acute Myeloid Leukemia from Returning After Treatment — National Cancer Institute (NCI)
• Study on Oral Decitabine and Cedazuridine (ASTX727) with Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients — National Cancer Institute (NCI)
• Testing New Treatments for Newly Diagnosed, Untreated Patients with High-Risk Acute Myeloid Leukemia (AML) — National Cancer Institute (NCI)
• Study on Topotecan, Carboplatin, and Veliparib for Treating Advanced Blood Disorders and Leukemia — National Cancer Institute (NCI)
• Study on Total Marrow and Lymphoid Irradiation Before Stem Cell Transplant for Patients with Myelodysplastic Syndrome or Acute Leukemia — City of Hope Medical Center
• Study on MGTA-456 for Patients with High-Risk Cancer — Masonic Cancer Center, University of Minnesota
• Study on Vedolizumab, Cyclophosphamide, and Tacrolimus to Prevent Graft Versus Host Disease in Patients Undergoing Stem Cell Transplant — City of Hope Medical Center
• Study Comparing Venetoclax and Azacitidine with Standard Chemotherapy in Acute Myeloid Leukemia (AML) — Massachusetts General Hospital
• Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia — M.D. Anderson Cancer Center
• Study on Venetoclax and Azacitidine for Treating Acute Myeloid Leukemia After Stem Cell Transplant — M.D. Anderson Cancer Center
• Study on Venetoclax and CLAG-M for Treating Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms — University of Washington
• Study on Venetoclax and HMA Treatment for Older Adults with FLT3 Mutated Acute Myeloid Leukemia (AML) — National Cancer Institute (NCI)
• Study on Venetoclax and Chemotherapy Before Donor Stem Cell Transplant for Treating Acute Myelogenous Leukemia or Myelodysplastic Syndrome — M.D. Anderson Cancer Center
• Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) — LLS PedAL Initiative, LLC
• Study on Venetoclax with Cladribine, Cytarabine, and Azacitidine for Newly Diagnosed Monocytic AML and Mutated AML — OHSU Knight Cancer Institute
• Study on Venetoclax to Improve Outcomes of Chemotherapy in Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome — M.D. Anderson Cancer Center
• Study on Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine for Treating Untreated Acute Myeloid Leukemia — M.D. Anderson Cancer Center
• Ziftomenib for Treating Acute Myeloid Leukemia with NPM1 Mutation or KMT2A Rearrangement in Patients Not Eligible for Standard Therapy — Uma Borate
• Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies — Orca Biosystems, Inc.
• Study on Bleximenib for Patients with Acute Leukemia — Janssen Research & Development, LLC
• Study on the Safety and Effectiveness of CTX131 for Adults with Difficult-to-Treat Blood Cancers — CRISPR Therapeutics
• Study on APG-115 Alone or Combined with Azacitidine for Patients with AML, CMML, or MDS — Ascentage Pharma Group Inc.
• Study Comparing Azacitidine and Venetoclax with Stem Cell Transplant in People Aged 65 and Older with Acute Myeloid Leukemia — Memorial Sloan Kettering Cancer Center
• A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies — Sanofi
• Study on Two Schedules of MS275 and 5AC for Treating Acute Myeloid Leukemia in Older Adults — Hetty Carraway
• Study on Azacitidine and Venetoclax for Initial Treatment and Maintenance in Elderly Patients with Acute Myeloid Leukemia (AML) — University of Colorado, Denver
• Study on Bortezomib and Sorafenib Tosylate for Newly Diagnosed Acute Myeloid Leukemia — National Cancer Institute (NCI)
• Study on CPX-351 or CLAG-M Treatment for Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Less-Fit Patients — Fred Hutchinson Cancer Center
• Study on DEC-C and Thioguanine for Relapsed or Refractory Acute Myeloid Leukemia (AML) — Joseph Jurcic
• Study on Decitabine, Venetoclax, and Ponatinib for Treating Philadelphia Chromosome-Positive Leukemia — M.D. Anderson Cancer Center
• Study on Cladribine-Based Chemotherapy for Treating Relapsed or Hard-to-Treat Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome — Medical College of Wisconsin
• Study on Enasidenib Maintenance Therapy After Stem Cell Transplant in Patients with IDH2 Mutation — City of Hope Medical Center
• Access to ABBV-787 Before Official Approval — AbbVie

Looking for a program not shown above? Search the full catalog for “Acute Myeloid Leukemia” to see every match including additional filters.